
Sigachi laboratories is listed on the Metropolitan Stock Exchange of India. It is having a Regd. Office at S.No. 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, (formerly Jinnaram Mandal), Sangareddy District, (formerly Medak District), Telangana. The company mainly gets its income from Pharmaceutical Products (Bulk Drugs and Drug Intermediates) and Interest on loans/ ICDs, Fixed Deposits.
| Price Per Equity Share | ₹ 52 |
| Lot Size | 1000 Shares |
| 52 Week High | ₹ 52 |
| 52 Week Low | ₹ 52 |
| Depository | NSDL & CDSL |
| PAN Number | AACCS8220M |
| ISIN Number | INE368H01018 |
| CIN | L24230TG1994PLC018786 |
| RTA | Venture Capital and Corporate Investments |
| Market Cap (in cr.) | ₹ 35 |
| P/E Ratio | 17.81 |
| P/B Ratio | 0.97 |
| Debt to Equity | 0 |
| ROE (%) | 5.47 |
| Book Value | 53.47 |
| Face Value | 10 |
| Total Shares | 6753100 |
| P&L Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 348 | 260 | 195 | 374 |
| Cost of Material Consumed | 0 | 0 | 0 | 0 |
| Gross Margins | 100 | 100 | 100 | 100 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Employee Benefit Expenses | 29 | 34 | 36 | 39 |
| Other Expenses | 26 | 15 | 17 | 93 |
| EBITDA | 293 | 211 | 142 | 242 |
| OPM | 84.2 | 81.15 | 72.82 | 64.71 |
| Other Income | 38 | 44 | 50 | 62 |
| Finance Cost | 0 | 0 | 0 | 0 |
| D&A | 17 | 17 | 19 | 23 |
| EBIT | 276 | 194 | 123 | 219 |
| EBIT Margins | 79.31 | 74.62 | 63.08 | 58.56 |
| PBT | 314 | 238 | 173 | 281 |
| PBT Margins | 90.23 | 91.54 | 88.72 | 75.13 |
| Tax | 38 | 38 | 42 | 84 |
| PAT | 276 | 200 | 131 | 197 |
| NPM | 79.31 | 76.92 | 67.18 | 52.67 |
| EPS | 3.78 | 2.74 | 1.79 | 2.69 |
| Financial Ratios | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | 84.2 | 81.15 | 72.82 | 64.71 |
| Net Profit Margin | 79.31 | 76.92 | 67.18 | 52.67 |
| Earning Per Share (Diluted) | 3.78 | 2.74 | 1.79 | 2.69 |
| P&L Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 348 | 260 | 195 | 374 |
| Cost of Material Consumed | 0 | 0 | 0 | 0 |
| Gross Margins | 100 | 100 | 100 | 100 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Employee Benefit Expenses | 29 | 34 | 36 | 39 |
| Other Expenses | 26 | 15 | 17 | 93 |
| EBITDA | 293 | 211 | 142 | 242 |
| OPM | 84.2 | 81.15 | 72.82 | 64.71 |
| Other Income | 38 | 44 | 50 | 62 |
| Finance Cost | 0 | 0 | 0 | 0 |
| D&A | 17 | 17 | 19 | 23 |
| EBIT | 276 | 194 | 123 | 219 |
| EBIT Margins | 79.31 | 74.62 | 63.08 | 58.56 |
| PBT | 314 | 238 | 173 | 281 |
| PBT Margins | 90.23 | 91.54 | 88.72 | 75.13 |
| Tax | 38 | 38 | 42 | 84 |
| PAT | 276 | 200 | 131 | 197 |
| NPM | 79.31 | 76.92 | 67.18 | 52.67 |
| EPS | 3.78 | 2.74 | 1.79 | 2.69 |
| Financial Ratios | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | 84.2 | 81.15 | 72.82 | 64.71 |
| Net Profit Margin | 79.31 | 76.92 | 67.18 | 52.67 |
| Earning Per Share (Diluted) | 3.78 | 2.74 | 1.79 | 2.69 |